Corrigendum to “Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells” [Biomaterials 37 (2015) 405–414] (Biomaterials (2015) 37 (405–414), (S0142961214010655), (10.1016/j.biomaterials.2014.10.018));Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells

Biomaterials

Volumn 37, Issue , 2015, Pages 405-414

  Sun, Rong ^a   Liu, Yang ^b   Li, Shi Yong ^b   Shen, Song ^b   Du, Xiao Jiao ^b   Xu, Cong Fei ^a   Cao, Zhi Ting ^a   Bao, Yan ^b   Zhu, Yan Hua ^b   Li, Ya Ping ^c   Yang, Xian Zhu ^b   Wang, Jun ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

All trans retinoic acid; Cancer stem cell; Co delivery; Combination therapy; Doxorubicin

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOLOGY; EMULSIFICATION; NANOPARTICLES; ONCOLOGY; STEM CELLS; TARGETED DRUG DELIVERY; TUMORS;

ALL-TRANS RETINOIC ACIDS; CANCER STEM CELLS; CO DELIVERIES; COMBINATION THERAPY; DOXORUBICIN;

DISEASES;

DOXORUBICIN; NANOPARTICLE; RETINOIC ACID; CYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CANCER THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; EMULSION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INCIDENCE; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; SELF CONCEPT; TREATMENT FAILURE; TUMOR CELL; TUMOR GROWTH; ANIMAL; BLOOD; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NEOPLASMS; NONOBESE DIABETIC MOUSE; PARTICLE SIZE; PATHOLOGY; SCID MOUSE; STATIC ELECTRICITY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INJECTIONS, INTRAVENOUS; MICE, INBRED NOD; MICE, SCID; NANOPARTICLES; NEOPLASMS; NEOPLASTIC STEM CELLS; PARTICLE SIZE; PROLIFERATING CELL NUCLEAR ANTIGEN; STATIC ELECTRICITY; TRETINOIN;

EID: 84922212608     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2020.120373     Document Type: Erratum

References (56)

1. Doane T.L., Burda C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev 2012, 4:2885-2911.
2. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered sirna via targeted nanoparticles. Nature 2010, 464:1067-1070.
3. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
5. Yuan Y.Y., Mao C.Q., Du X.J., Du J.Z., Wang F., Wang J. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor. Adv Mater 2012, 24:5476-5480.
6. Iyer A.K., Singh A., Ganta S., Amiji M.M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013, 65:1784-1802.
7. Yang X.Z., Du X.J., Liu Y., Zhu Y.H., Liu Y.Z., Li Y.P., et al. Rational design of polyion complex nanoparticles to overcome cisplatin resistance in cancer therapy. Adv Mater 2014, 26:931-936.
8. Meng H., Liong M., Xia T., Li Z., Ji Z., Zink J.I., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and p-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
9. Sarfati G., Dvir T., Elkabets M., Apte R.N., Cohen S. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. Biomaterials 2011, 32:152-161.
10. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
11. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
12. Zhou L., Jiang Y., Yan T., Di G., Shen Z., Shao Z., et al. The prognostic pole of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat 2010, 122:795-801.
13. Yu F.Y., Yao H., Zhu P.C., Zhang X.Q., Pan Q.H., Gong C., et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
14. McAuliffe S.M., Morgan S.L., Wyant G.A., Tran L.T., Muto K.W., Chen Y.S., et al. Targeting notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 2012, 109:2939-2948.
15. Domingo-Domenech J., Vidal S.J., Rodriguez-Bravo V., Castillo-Martin M., Quinn S.A., Rodriguez-Barrueco R., et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012, 22:373-388.
16. Campos B., Wan F., Farhadi M., Ernst A., Zeppernick F., Tagscherer K.E., et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010, 16:2715-2728.
17. Malanchi I., Santamaria-Martinez A., Susanto E., Peng H., Lehr H.A., Delaloye J.F., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
18. Kim S.S., Rait A., Kim E., Pirollo K.F., Nishida M., Farkas N., et al. Ananoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano 2014, 8:5494-5514.
19. Li R.J., Ying X., Zhang Yan, Ju R.J., Wang X.X., Yao H.J., et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. JControl Release 2011, 49:281-291.
20. Yang C.P., He X.F., Song L.N., Zhan X., Zhang Y., Dou J., et al. Gamma-Fe2O3 nanoparticles increase therapeutic efficacy of combination with paclitaxel and anti-ABCG2 monoclonal antibody on multiple myeloma cancer stem cells in mouse model. JBiomed Nanotechnol 2014, 10:336-344.
21. Zhao Y., Alakhova D.Y., Kabanov A.V. Can nanomedicines kill cancer stem cells?. Adv Drug Deliv Rev 2013, 65:1763-1783.
22. Yang C., Xiong F., Wang J., Dou J., Chen J., Chen D., et al. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine 2014, 9:45-60.
23. Du J.Z., Du X.J., Mao C.Q., Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. JAm Chem Soc 2011, 133:17560-17563.
24. Sun T.M., Wang Y.C., Wang F., Du J.Z., Mao C.Q., Sun C.Y., et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014, 35:836-845.
25. Gupta P.B., Fillmore C.M., Jiang G.Z., Shapira S.D., Tao K., Kuperwasser C., et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 147:1197.
26. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011, 108:7950-7955.
27. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
28. van der Horst G., Bos L., van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 2012, 10:995-1009.
29. Hu C.M., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010, 1:323-334.
30. Lehar J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009, 27:659-666.
31. Prashant S., Vineet M., Amit K., Vikram K., Venkatesh Teja B., Dharmendra C., et al. Nanoemulsion based concomitant delivery of curcumin and etoposide: impact on cross talk between prostate cancer cells and osteoblast during metastasis. JBiomed Nanotechnol 2014, 10:3381-3391.
32. Guo Q.F., Li X.L., Yang Y., Wei J., Zhao Q., Luo F., et al. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles. JBiomed Nanotechnol 2014, 10:227-237.
33. MacDiarmid J.A., Amaro-Mugridge N.B., Madrid-Weiss J., Sedliarou I., Wetzel S., Kochar K., et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009, 27:643-651.
34. Shi S., Shi K., Tan L.W., Qu Y., Shen G.B., Chu B.Y., et al. The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin. Biomaterials 2014, 35:4536-4547.
35. Sun T.M., Du J.Z., Yao Y.D., Mao C.Q., Dou S., Huang S.Y., et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5:1483-1494.
36. Wei W., Lv P.P., Chen X.M., Yue Z.G., Fu Q., Liu S.Y., et al. Codelivery of mtert siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials 2013, 34:3912-3923.
37. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
38. Ginestier C., Wicinski J., Cervera N., Monville F., Finetti P., Bertucci F., et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009, 8:3297-3302.
39. Gudas L.J., Wagner J.A. Retinoids regulate stem cell differentiation. JCell Physiol 2011, 226:322-330.
40. Zhang Y., Guan D.X., Shi J., Gao H., Li J.J., Zhao J.S., et al. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. JHepatol 2013, 59:1255-1263.
41. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. JControl Release 2005, 103:405-418.
42. Ogawara K., Un K., Tanaka K., Higaki K., Kimura T. Invivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. JControl Release 2009, 133:4-10.
43. Vinogradov S., Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine 2012, 7:597-615.
44. Yang X.Z., Dou S., Sun T.M., Mao C.Q., Wang H.X., Wang J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. JControl Release 2011, 156:203-211.
45. Hu Y., Smyth G.K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. JImmunol Methods 2009, 347:70-78.
46. Damaraju V.L., Bouffard D.Y., Wong C.K., Clarke M.L., Mackey J.R., Leblond L., et al. Synergistic activity of troxacitabine (Troxatyl (TM)) and gemcitabine in pancreatic cancer. BMC Cancer 2007, 7:121.
47. Chou T.C. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res 2010, 70:440-446.
48. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
49. Douville J., Beaulieu R., Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 2009, 18:17-25.
50. Noh K.H., Kim B.W., Song K.H., Cho H., Lee Y.H., Kim J.H., et al. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. JClin Invest 2012, 122:4077-4093.
51. Leis O., Eguiara A., Lopez-Arribillaga E., Alberdi M.J., Hernandez-Garcia S., Elorriaga K., et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012, 31:1354-1365.
52. Liu C.G., Lu Y., Wang B.B., Zhang Y.J., Zhang R.S., Chen B., et al. Clinical implications of stem cell gene oct-4 expression in breast cancer. Ann Surg 2011, 253:1165-1171.
53. Sun C.Y., Dou S., Du J.Z., Yang X.Z., Li Y.P., Wang J. Doxorubicin conjugate of poly(ethylene glycol)-block polyphosphoester for cancer therapy. Adv Healthc Mater 2014, 3:261-272.
54. Kawakami S., Opanasopit P., Yokoyama M., Chansri N., Yamamoto T., Okano T., et al. Biodistribution characteristics of all-trans retinoic acid incorporated in liposomes and polymeric micelles following intravenous administration. JPharm Sci 2005, 94:2606-2615.
55. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
56. Ke X.Y., Lin Ng V.W., Gao S.J., Tong Y.W., Hedrick J.L., Yang Y.Y. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 2014, 35:1096-1108.